T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer.

ABSTRACT:

Background

Endometrial cancer ranks among the most prevalent gynecological malignancies, with a notable increase in incidence, especially among women under 40. Although most patients are diagnosed at an early stage and have an excellent prognosis, the outcome for metastatic and recurrent cases remains poor. Current treatment for advanced-stage disease includes chemotherapy, hormonal therapy and checkpoint inhibitors. The clinical response rate to immunotherapy varies depending on the molecular subtype of endometrial carcinoma. Novel immunotherapeutic strategies are needed to improve patient survival, particularly across molecular subtypes. CD276 (cluster of differentiation 276, B7-H3) is emerging as a promising immunotherapy target due to its expression across multiple tumor types.

SUBMITTER: Greiner SM 

PROVIDER: S-EPMC12291243 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature